TScan Therapeutics

TCRX

Market cap $99.9M

Overview Fund Activity

1.76 USD

-0.09

4.86%

At close Updated Sep 12, 4:00 PM EDT

Pre-market

After hours

1.79

+0.03

1.7%

1 day

-4.86%

5 days

-7.85%

1 month

5.39%

3 months

9.32%

6 months

-2.22%

Year to date

-43.04%

1 year

-68.23%

5 years

-83.24%

10 years

-83.24%

About: TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.

Employees: 210

Healthcare Biotechnology

0

Funds holding %

of 7,462 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

44% more repeat investments, than reductions

Existing positions increased: 26 | Existing positions reduced: 18

6% less capital invested

Capital invested by funds: $55.4M [Q1] → $51.8M (-$3.56M) [Q2]

8.44% less ownership

Funds ownership: 76.73% [Q1] → 68.28% (-8.44%) [Q2]

13% less funds holding

Funds holding: 92 [Q1] → 80 (-12) [Q2]

20% less funds holding in top 10

Funds holding in top 10: 5 [Q1] → 4 (-1) [Q2]

38% less first-time investments, than exits

New positions opened: 20 | Existing positions closed: 32

See Fund Rankings

Financial journalist opinion

TScan Therapeutics to Participate in Upcoming Investor Conferences

WALTHAM, Mass., Sept. 03, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced that the Company will participate in the following upcoming investor conferences:

TScan Therapeutics to Participate in Upcoming Investor Conferences

Zacks Investment Research

TScan Therapeutics, Inc. (TCRX) Reports Q2 Loss, Beats Revenue Estimates

TScan Therapeutics, Inc. (TCRX) came out with a quarterly loss of $0.28 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.28 per share a year ago.

TScan Therapeutics, Inc. (TCRX) Reports Q2 Loss, Beats Revenue Estimates

TScan Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Two-year relapse data from ALLOHA™ Phase 1 heme trial to be presented by end of year Expects to dose first solid tumor patients with multiplex TCR-T in the third quarter of 2025 Cash, cash equivalents, and marketable securities continue to fund operations into the first quarter of 2027 WALTHAM, Mass., Aug. 12, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today reported financial results for the second quarter ended June 30, 2025, and provided a corporate update.

TScan Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

TScan Therapeutics Announces Upcoming Presentation at the Jefferies Global Healthcare Conference

WALTHAM, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced that the Company will present at the Jefferies Global Healthcare Conference being held at the Marriott Marquis in New York, NY on Wednesday, June 4, 2025 at 4:55 p.m. Eastern Time.

TScan Therapeutics Announces Upcoming Presentation at the Jefferies Global Healthcare Conference

Zacks Investment Research

TScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Tops Revenue Estimates

TScan Therapeutics, Inc. (TCRX) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to loss of $0.32 per share a year ago.

TScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Tops Revenue Estimates

TScan Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

Updates from the PLEXI-T™ solid tumor and ALLOHA™ heme Phase 1 clinical trials anticipated by end of year On-track to file IND application for TSC-102-A0301 (CD45; HLA-A*03:01) to FDA in the second half of the year Appointed commercial leader Stephen Camiolo as Senior Vice President, Market Access Cash, cash equivalents, and marketable securities continue to fund operations into the first quarter of 2027 WALTHAM, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today reported financial results for the three months ended March 31, 2025, and provided a corporate update.

TScan Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 28th Annual Meeting

WALTHAM, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced the acceptance of an abstract for poster presentation at the upcoming American Society of Gene and Cell Therapy (ASGCT) 28ᵗʰ Annual Meeting being held May 13 – 17 in New Orleans, LA as well as virtually.

TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 28th Annual Meeting

TScan Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

WALTHAM, Mass., March 31, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced that the Company will participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Monday, April 7, 2025 at 9:30 a.m. Eastern Time.

TScan Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

TScan Therapeutics Appoints Commercial Leader Stephen Camiolo as Senior Vice President, Market Access

Mr. Camiolo brings to TScan demonstrated commercial readiness and cell therapy launch experience Mr. Camiolo brings to TScan demonstrated commercial readiness and cell therapy launch experience

TScan Therapeutics Appoints Commercial Leader Stephen Camiolo as Senior Vice President, Market Access

TScan: 2 Major Milestones Of TSC-101 To Carry Tide In 2025

Additional data from phase 1 ALLOHA study, using TSC-101 for the treatment of patients with hematological malignancies of those undergoing allogeneic haploidentical HSCT, expected by end of 2025. Barring positive feedback from regulatory authorities, the company hopes to develop TSC-101 for AML, MDS, ALL patients who undergo HSCT in a pivotal study in the 2nd half of 2025. The company is developing multiplex TCR-Ts for treatment of patients with solid tumors, with phase 1 PLEXI-T trial data anticipated in the second half of 2025.

TScan: 2 Major Milestones Of TSC-101 To Carry Tide In 2025

See News Rankings

Charts implemented using Lightweight Charts™